Supporting this hypothesis, CDKN1A gene expression levels in the PCGP cohort is on average six- to seven-fold lower in pediatric T-ALL compared to B-ALL, AML or brain tumors. The gene discussed is CDKN1A; the disease is brain neoplasm.